Tormod Kyrre Guren

Overlege
ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF
Overlege
ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF

Resultater Resultater

High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond.

Edsjö, Anders; Russnes, Hege Elisabeth Giercksky; Lehtiö, Janne; Tamborero, David; Hovig, Eivind; Stenzinger, Albrecht; Rosenquist, Richard; Janowska, Agnieszka; Rioja, Alba López; Razzak, Ali mfl.. 2024, Journal of Internal Medicine. Uu, KAROLINSKA, FHI, TÜ, SPANIA, KROATIA, SVERIGE, MYANMAR, SKÅNE, HiS, UNGARN, HUH, POLEN, HYKS, NEDERLAND, KI, PORTUGAL, HCB, Lu, TUK, OUS, SUS, UdSdM, IEO, RH, CLB, UIO, LUMC, LITAUEN, VUVitenskapelig artikkel

Incidence patterns of colorectal cancer in Norway 1993-2022 by age, site, and morphology.

Ystgaard, Mari Fjørtoft; Myklebust, Tor Åge; Smeby, Jørgen; Larsen, Inger Kristin; Guren, Tormod Kyrre; Kure, Elin Wenche Hegland; Tveit, Magne Kjell; Glimelius, Bengt; Guren, Marianne; Hamfjord, Julian. 2024, 2024 ASCO Gastrointestinal Cancers Symposium. AKADEMISKA, HELSEMR, FHI, UIO, OUSPoster

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

Desai, Jayesh; Alonso, Guzman; Kim, Se Hyun; Cervantes, Andres; Karasic, Thomas; Medina, Laura; Shacham-Shmueli, Einat; Cosman, Rasha; Falcon, Alejandro; Gort, Eelke mfl.. 2023, Nature Medicine. UTA, UdV, CITYOFHOPE, SPANIA, MCGILL, PENN, BELGIA, UHN, UNSW, UoU, YU, USA, MSKCC, H12O, MELB, UMC, HUVR, SØRKOREA, UdSdP, OUS, GENENTECH, WUM, HMS, ICM, UCI, ITALIAVitenskapelig artikkel

Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.

Høland, Maren; Berg, Kaja Christine Graue; Eilertsen, Ina Andrassy; Bjerkehagen, Bodil; Kolberg, Matthias; Pedersen, Kjetil Boye; Lingjærde, Ole Christian; Guren, Tormod Kyrre; Mandahl, Nils; van den Berg, Eva mfl.. 2023, EBioMedicine. Lu, UIO, UMCG, OUS, IORVitenskapelig artikkel

Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT Inhibitor) in Patients with Advanced Breast Cancer with PI3K Pathway Dependence.

Gupta, S.; Munster, P.; Hollebecque, A.; Argiles, G.; Guren, Tormod Kyrre; Cheng, J.; Wang, R.; Swift, A.; Tosolini, A.; Piha-Paul, S.. 2014, Annals of Oncology. UNIVCAL, VHIR, IGR, OUS, MOFFITT, MERCK, UTMVitenskapelig artikkel

1 - 5 av 72 | Neste | Siste »